New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
05:50 EDTMDCOThe Medicines Co. price target raised to $38 from $30 at WallachBeth
WallachBeth raised its price target for The Medicines Co. shares following the company's Q4 results and reiterates a Buy rating on the stock.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
07:05 EDTMDCOMedicines Company says BARDA exercises option on Carbavance pact
The Medicines Company announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of CARBAVANCE. CARBAVANCE is the combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor that is targeted for treatment of multi-drug resistant gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae. The cost-share contract with BARDA was initiated in 2014 and extends over 5 years. The award of this third option brings the total commitment from BARDA to $53.8M. If all options are exercised in the contract, it would bring the total value of the award to approximately $90M.
September 25, 2015
09:01 EDTMDCOThe Medicines Co. receives CHMP positive opinion for Ionsys
Subscribe for More Information
September 22, 2015
07:53 EDTMDCOThe Medicines Co. management to meet with Leerink
Meetings to be held in Boston on September 24-25 hosted by Leerink.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use